Goldman Sachs analysts removed Insmed (INSM) from the firm’s US Conviction List as part of its monthly update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed treatment of Duchenne muscular dystrophy granted orphan designation
- Insmed price target raised to $144 from $126 at Morgan Stanley
- Insmed’s Promising Future: Buy Rating Backed by Brinsupri Approval and Strategic Growth Prospects
- Insmed price target raised to $135 from $111 at JPMorgan
- Insmed initiated with an Outperform at William Blair